CRDF
Cardiff Oncology, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.39
+6.92%Sep 14, 2026, 13:32 UTC
Cardiff Oncology and Nerviano Medical Sciences signed a confidential settlement agreement on September 14, 2026 to dismiss their litigation with prejudice and exchange mutual releases, with no monetary payment or admission of liability.
Sep 14, 2026, 12:30 UTC
Cardiff Oncology and Nerviano Medical Sciences amended their 2017 exclusive license agreement.
Source:Aug 11, 2026, 20:10 UTC
Cardiff Oncology presented positive Phase 2 CRDF-004 data at ASCO supporting advancement of 30 mg onvansertib plus FOLFIRI/bevacizumab into a planned registrational program for first-line RAS-mutated metastatic colorectal cancer.
Source:Jul 15, 2026, 12:00 UTC
Cardiff Oncology entered into definitive agreements for a registered direct offering of shares of its common stock and warrants.
Source: